Heteroresistance to cefepime in Pseudomonas aeruginosa bacteremia.
Heteroresistance to antibiotic agents can lead to the diagnostic and therapeutic failures; however, cefepime heteroresistance (FEP-HR) in P. aeruginosa bacteremia has not been characterized to date. The primary goal of this study was to investigate the molecular epidemiology, mechanisms, and risk factors for cefepime-heteroresistant P. aeruginosa bacteremia over approximately six years in Southwest China. We observed a high prevalence (57.3%) of heteroresistance to cefepime during the study period, and these FEP-HR isolates were not clonally relatedness. Mechanistic studies revealed that AmpC hyperproduction contributed to the development of this phenomenon. In addition, patients with advanced age, hematologic malignancies, central venous catheters, and previous cephalosporins therapy were identified as independent risk factors for the acquisition of FEP-HR P. aeruginosa bacteremia. Furthermore, patients infected with FEP-HR were, in general, at a greater risk for an adverse prognosis compared to those with non-FEP-HR. More importantly, characterization of three successive P. aeruginosa isolates recovered from the same patient revealed that heteroresistance can act as an intermediate stage during the evolution from susceptibility to full resistance in patients undergoing antibiotic therapy for prolonged periods. Our findings emphasized the necessity of antimicrobial stewardship programs in clinical settings as well as the need for some rapid screening methods for detecting this phenomenon.